I did a brief online literature search to try to answer B's question.
Rituximab was used for at least one patient with CIDP who was also being treated by plasmapheresis. The reference is:
Chronic inflammatory demyelinating polyradiculoneuropathy in a patient with systemic lupus erythematosus and good outcome with rituximab treatment. </pubmed/21922339>
Sanz PG, García Méndez CV, Cueto AL, Silva VB, Walther JC, Diez RA, Martins S, Giannaula RJ.
Rheumatol Int. 2012 Dec;32(12):4061-3. doi: 10.1007/s00296-■■■■■■■■-5. Epub 2011 Sep 16.
The abstract indicates that rituximab was successful in this case. To get more information, you need access to the journal article, which I don't have.
Rituximab has also been used by patients taking plasmapheresis for other autoimmune disorders. For example, see:
Rituximab Can Be Combined With Daily Plasma Exchange to Achieve Effective B-Cell Depletion and Clinical Improvement in Acute Autoimmune TTP
Kamran Darabi, MD, Anders H. Berg, MD, PhD
Am J Clin Pathol. 2006;125(4):592-597
http://ajcp.ascpjournals.org/content/125/4/592.full.pdf
Interestingly, plasmapheresis can be used as an antidote when rituximab causes severe adverse effects because the removal of the patient's plasma also removes rituximab. Therefore, it seems better to have plasmapheresis prior to rituximab treatment, to avoid removing rituximab before it has done it's job.